CXCR4 and neoplasm: AMD3100 (Plerixafor) is a selective CXCR4 chemokine receptor antagonist that blocks the interaction between CXCR4 and its natural ligand CXCL12, a critical axis involved in various pathological conditions, including HIV-1 infection, tumor progression, and metastasis.